OBJECTIVE: To describe the most frequent adverse reactions produced by the human papillomavirus (HPV) vaccine. DESIGN: Cross-sectional descriptive study using a telephone survey. SETTING: A province in the Andalusian Public Health System. PARTICIPANTS: Females vaccinated against HPV in Andalusia, selected by simple random sampling representative of the province. MAIN MEASUREMENTS: A total of 3,135 telephone calls were made by the public service "Health Answers" using telephone operators supervised by health personnel. RESULTS: Of the 2,880 calls that fulfilled the inclusion criteria, 1,207 people (41.9% response) took part in the survey. Of the 2,124 surveys made there was some type of adverse reaction (fever, inflammation, pain or rash) in 467 doses (22%): 6.6% was fever, 49.5% inflammation, 72.4% pain, and 6% a rash. CONCLUSIONS: It can be said that HPV vaccine is safe, which is in agreement with that published in the summary of the product characteristics and in the literature.
OBJECTIVE: To describe the most frequent adverse reactions produced by the human papillomavirus (HPV) vaccine. DESIGN: Cross-sectional descriptive study using a telephone survey. SETTING: A province in the Andalusian Public Health System. PARTICIPANTS: Females vaccinated against HPV in Andalusia, selected by simple random sampling representative of the province. MAIN MEASUREMENTS: A total of 3,135 telephone calls were made by the public service "Health Answers" using telephone operators supervised by health personnel. RESULTS: Of the 2,880 calls that fulfilled the inclusion criteria, 1,207 people (41.9% response) took part in the survey. Of the 2,124 surveys made there was some type of adverse reaction (fever, inflammation, pain or rash) in 467 doses (22%): 6.6% was fever, 49.5% inflammation, 72.4% pain, and 6% a rash. CONCLUSIONS: It can be said that HPV vaccine is safe, which is in agreement with that published in the summary of the product characteristics and in the literature.
Authors: Jim P Buttery; Simon Madin; Nigel W Crawford; Sonja Elia; Sophie La Vincente; Sarah Hanieh; Lindsay Smith; Bruce Bolam Journal: Med J Aust Date: 2008-09-01 Impact factor: 7.738
Authors: Luisa L Villa; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Kevin A Ault; Anna R Giuliano; Cosette M Wheeler; Laura A Koutsky; Christian Malm; Matti Lehtinen; Finn Egil Skjeldestad; Sven-Eric Olsson; Margareta Steinwall; Darron R Brown; Robert J Kurman; Brigitte M Ronnett; Mark H Stoler; Alex Ferenczy; Diane M Harper; Gretchen M Tamms; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Frank J Taddeo; Kathrin U Jansen; Mark T Esser; Heather L Sings; Alfred J Saah; Eliav Barr Journal: Lancet Oncol Date: 2005-05 Impact factor: 41.316
Authors: Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Keith S Reisinger; Stan L Block; Eduardo Lazcano-Ponce; Rudiwilai Samakoses; Mark T Esser; Joanne Erick; Derek Puchalski; Katherine E D Giacoletti; Heather L Sings; Suzanne Lukac; Frances B Alvarez; Eliav Barr Journal: Pediatr Infect Dis J Date: 2007-03 Impact factor: 2.129
Authors: Ryo Konno; Kurt O Dobbelaere; Olivier O Godeaux; Shinobu Tamura; Hiroyuki Yoshikawa Journal: Int J Gynecol Cancer Date: 2009-07 Impact factor: 3.437